Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Neurosurgery

Free Subscription Articles published in Int J Radiat Oncol Biol Phys Retrieve available abstracts of 152 articles: HTML format

Single Articles

December 2025
1. DONOVAN EK, Schnarr KL, Greenspoon JN, Wright JR, et al
   STEREOTACTIC BODY RADIOTHERAPY (SBRT) BOOST FOLLOWING URGENT 3D CONFORMAL RADIOTHERAPY FOR METASTATIC EPIDURAL SPINAL CORD COMPRESSION (MESCC): A PHASE 1 FEASIBILITY STUDY.
   Int J Radiat Oncol Biol Phys. 2025 Dec 23:S0360-3016(25)06608.
   PubMed     Abstract available
   
   
   
2. THOMPSON LL, Amin PM, Shah S, Lipson SM, et al
   Associations Between G8 Geriatric Screening Score, Charlson Comorbidity Index, AI-Based Age Phenotype, and Overall Survival in Older Adults With Stage I-II Non-Small Cell Lung Cancer.
   Int J Radiat Oncol Biol Phys. 2025;123:1295-1305.
   PubMed     Abstract available
   
   
   November 2025
3. FLEURY E, Pignol JP, Kilic E, van Rij C, et al
   Stereotactic Radiation Therapy or Protons for Uveal Melanoma Patients? An Artificial Intelligence (AI)-Based Clinical Treatment Decision-Making Tool Predicting Doses To Radiation Therapy Constraints.
   Int J Radiat Oncol Biol Phys. 2025;123:1159-1164.
   PubMed     Abstract available
   
   
   
4. JACKSON CB, Boe LA, Zhang L, Apte A, et al
   Histologic Classifier of Radiosensitivity to Spine Stereotactic Body Radiation Therapy.
   Int J Radiat Oncol Biol Phys. 2025;123:829-838.
   PubMed     Abstract available
   
   
   
5. COOPER S, Westley RL, Biscombe K, Dunlop A, et al
   HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy.
   Int J Radiat Oncol Biol Phys. 2025;123:773-782.
   PubMed     Abstract available
   
   
   October 2025
6. MADISON CJ, Lynch JA, Duvall SL, Alba PR, et al
   Development and Validation of a Computable Radiation Therapy Phenotype.
   Int J Radiat Oncol Biol Phys. 2025;123:583-592.
   PubMed     Abstract available
   
   
   
7. RAMADAN S, Loblaw A, Dhar A, Fakir H, et al
   PSMA MRI Guided prOstate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I/II Trial.
   Int J Radiat Oncol Biol Phys. 2025;123:395-405.
   PubMed     Abstract available
   
   
   
8. TOM MC, Ghia AJ
   Stereotactic Body Radiation Therapy for Epidural Spinal Cord Compression: Treat Aggressively Now, Avoid Recurrence Later.
   Int J Radiat Oncol Biol Phys. 2025;123:330.
   PubMed    
   
   
   
9. ACEVEDO LA, Awan M
   Radionuclear ESCCalation: Local Therapy for Epidural Spinal Cord Compression in the Context of Peptide Receptor Radionuclide Therapy.
   Int J Radiat Oncol Biol Phys. 2025;123:328-329.
   PubMed    
   
   
   September 2025
10. TSANG DS, Murphy E, Salerno KE, Parkes J, et al
    Stereotactic Radiation Therapy in Children and Young Adults: Can We Apply Adult Treatment Paradigms?
    Int J Radiat Oncol Biol Phys. 2025;123:43-53.
    PubMed     Abstract available
    
    
    August 2025
11. MARSHALL J, Bergman A, Karan T, Deyell MW, et al
    Toward the Use of Implanted Cardiac Leads or the Diaphragm for Active Respiratory Motion Management in Stereotactic Arrhythmia Radioablation.
    Int J Radiat Oncol Biol Phys. 2025;122:1344-1355.
    PubMed     Abstract available
    
    
    
12. LEE HI, Son J, Cho B, Goh Y, et al
    Development and Validation of a Prediction Model for Cardiac Events in Patients With Hepatocellular Carcinoma Undergoing Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:1272-1281.
    PubMed     Abstract available
    
    
    July 2025
13. GUEVARA B, Rezaei A, Baydoun A, Li Q, et al
    In Silico Evaluation of Direct-to-Unit, Single-Visit Celiac Plexus Pain Ablation Using Computed Tomography Guided Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:1054-1059.
    PubMed     Abstract available
    
    
    
14. PARSONS D, Domal S, Chambers E, Salazar D, et al
    Feasibility and Impact of a Radiation Therapy Technologist-Driven Workflow for Cone Beam Computed Tomography Guided Partial Breast Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:893-901.
    PubMed     Abstract available
    
    
    
15. CHUONG MD, Mittauer KE, Bassetti MF, Rojas C, et al
    Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2025;122:957-967.
    PubMed     Abstract available
    
    
    
16. SNYDER JE, Fast MF, Uijtewaal P, Borman PTS, et al
    Enhancing Delivery Efficiency on the Magnetic Resonance-Linac: A Comprehensive Evaluation of Prostate Stereotactic Body Radiation Therapy Using Volumetric Modulated Arc Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:976-985.
    PubMed     Abstract available
    
    
    
17. WEI L, Aryal MP, Rice J, Evans J, et al
    Assessing the Relationship Between MR-Based Functional Dose Metrics and Post-Stereotactic Body Radiation Therapy Albumin-Bilirubin Change.
    Int J Radiat Oncol Biol Phys. 2025;122:690-697.
    PubMed     Abstract available
    
    
    
18. LUKEZ A, Zhang L, Horwitz EM, Galloway TJ, et al
    Computed Tomography-Guided Online Adaptive Stereotactic Body Radiation Therapy for Liver Tumors: A Retrospective Study.
    Int J Radiat Oncol Biol Phys. 2025;122:659-667.
    PubMed     Abstract available
    
    
    
19. D'SOUZA A, Kang KH, Lattin JE, Kalaghchi B, et al
    Feasibility of Stereotactic Body Radiation Therapy for Pancreatic Tumors Abutting Organs at Risk Using Magnetic Resonance Guided Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:668-677.
    PubMed     Abstract available
    
    
    
20. MICHALET M, Valenzuela G, Nougaret S, Tardieu M, et al
    Development of Multiparametric Prognostic Models for Stereotactic Magnetic Resonance Guided Radiation Therapy of Pancreatic Cancers.
    Int J Radiat Oncol Biol Phys. 2025;122:678-689.
    PubMed     Abstract available
    
    
    
21. KISER K, Laugeman E, Beckert R, Kwon M, et al
    Minimizing Bowel Gas Artifact in Computed Tomography Guided Online Adaptive Radiation Therapy With Prolonged Supine Positioning.
    Int J Radiat Oncol Biol Phys. 2025;122:643-647.
    PubMed     Abstract available
    
    
    
22. WESTERHOFF JM, Scheepens JCM, van Wolffelaar FF, Bernchou U, et al
    Quality of Life and Toxicity in Patients With Pancreatic Ductal Adenocarcinoma Treated With Online Adaptive Stereotactic Magnetic Resonance Guided Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;122:698-708.
    PubMed     Abstract available
    
    
    
23. HOWARD TP, Ferguson D, Han Z, Mamon HJ, et al
    Magnetic Resonance-Guided Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation for Reirradiation in the Abdomen.
    Int J Radiat Oncol Biol Phys. 2025;122:752-759.
    PubMed     Abstract available
    
    
    
24. JOOYA A, Ly S, Dawson LA, Moreira A, et al
    Patient-Reported Quality-of-Life Outcomes After Abdominopelvic Stereotactic Body Radiation Therapy Using an MR-Linac System.
    Int J Radiat Oncol Biol Phys. 2025;122:770-775.
    PubMed     Abstract available
    
    
    
25. AKDEMIR EY, Herrera R, Gurdikyan S, Hodgson LC, et al
    Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Infradiaphragmatic Oligometastatic Disease: Disrupting the One-Size-Fits-All Paradigm.
    Int J Radiat Oncol Biol Phys. 2025;122:739-751.
    PubMed     Abstract available
    
    
    
26. VAN WERKHOVEN LA, Milder MTW, Schillemans W, Hoogeman MS, et al
    Computed Tomography Guided Online Adaptive Stereotactic Body Radiation Therapy for Lymph Node Oligometastases: Impact on Dose to Target and Organs at Risk.
    Int J Radiat Oncol Biol Phys. 2025;122:760-769.
    PubMed     Abstract available
    
    
    
27. VAN WERKHOVEN LA, Milder MTW, Hoogeman MS, van Werkhoven E, et al
    Results of a Single-Arm Phase 2 Clinical Trial: Online Adaptive Stereotactic Body Radiation Therapy for Abdominal-Pelvic Oligometastases.
    Int J Radiat Oncol Biol Phys. 2025;122:729-738.
    PubMed     Abstract available
    
    
    June 2025
28. YILMAZ MT, Cengiz M, Kahvecioglu A, Yigit E, et al
    Fifteen Years of Experience with Stereotactic Body Radiotherapy for Recurrent Head and Neck Cancers: A Detailed Analysis of Patients with Carotid Blowout Syndrome.
    Int J Radiat Oncol Biol Phys. 2025 Jun 25:S0360-3016(25)04486.
    PubMed     Abstract available
    
    
    May 2025
29. FARISELLI L, Marzoli SB, Morlino S, Pinzi V, et al
    Hypofractionated radiosurgery (25 Gy/5 fractions) for optic nerve sheath meningiomas: results from an exploratory phase 2 prospective trial.
    Int J Radiat Oncol Biol Phys. 2025 May 9:S0360-3016(25)00432.
    PubMed     Abstract available
    
    
    April 2025
30. ALFAIFI SA, Louie AV, Siva S, Guckenberger M, et al
    International Patterns of Practice for Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Are We All in Sync?: Global patterns of practice for SABR for early-stage NSCLC.
    Int J Radiat Oncol Biol Phys. 2025 Apr 29:S0360-3016(25)00390.
    PubMed     Abstract available
    
    
    
31. MARCHETTI M, Pinzi V, Gemma M, Cuccarini V, et al
    Hypo-fractionated versus single-session radiosurgery to preserve hearing in patients affected by sporadic vestibular schwannoma. The ACOUNEU randomized clinical trial.
    Int J Radiat Oncol Biol Phys. 2025 Apr 11:S0360-3016(25)00359.
    PubMed     Abstract available
    
    
    
32. SIMONE CB 2ND, Amini A, Chetty IJ, Choi JI, et al
    American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary.
    Int J Radiat Oncol Biol Phys. 2025 Apr 2:S0360-3016(25)00259.
    PubMed     Abstract available
    
    
    
33. CHAN AW, Zeng KL, Moore-Palhares D, Atenafu EG, et al
    Spine Stereotactic Body Radiation Therapy in Geriatric Patients: Implications of Age and Dose on Iatrogenic Vertebral Compression Fracture Risk.
    Int J Radiat Oncol Biol Phys. 2025;121:1185-1193.
    PubMed     Abstract available
    
    
    March 2025
34. MACCHIA G, Pezzulla D, Campitelli M, Lucci S, et al
    TREATMENT OF OLIGOMETASTATIC PARENCHYMAL LESIONS IN OVARIAN CANCER WITH STEREOTACTIC ABLATIVE RADIOTHERAPY: A MULTICENTER PROSPECTIVE PHASE II TRIAL (MITO RT3/RAD).
    Int J Radiat Oncol Biol Phys. 2025 Mar 31:S0360-3016(25)00262.
    PubMed     Abstract available
    
    
    
35. SANUKI N, Kimura T, Takeda A, Ariyoshi K, et al
    Final Results of a Multicenter Prospective Study of Stereotactic Body Radiation Therapy for Previously Untreated Solitary Primary Hepatocellular Carcinoma (The STRSPH Study).
    Int J Radiat Oncol Biol Phys. 2025;121:942-950.
    PubMed     Abstract available
    
    
    
36. HILL CS, Parkinson R, Jaffee EM, Sugar E, et al
    Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic
    Int J Radiat Oncol Biol Phys. 2025;121:930-941.
    PubMed     Abstract available
    
    
    
37. KLEBANER D, Pollom EL, Rahimy E, Gibbs IC, et al
    Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases.
    Int J Radiat Oncol Biol Phys. 2025 Mar 13:S0360-3016(25)00242.
    PubMed     Abstract available
    
    
    February 2025
38. UPADHYAY R, Elguindy ANM, Salts L, Donovan K, et al
    Boswellia serrata for cerebral radiation necrosis after radiosurgery for brain metastases.
    Int J Radiat Oncol Biol Phys. 2025 Feb 22:S0360-3016(25)00153.
    PubMed     Abstract available
    
    
    
39. REVERBERI C, Facondo G, Prisco A, Ceschia T, et al
    Pre-Operative Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer Patients with Gammapod Technology: Pathological Findings and Ki-67 Evaluation.
    Int J Radiat Oncol Biol Phys. 2025 Feb 22:S0360-3016(25)00152.
    PubMed     Abstract available
    
    
    
40. GAETA B, Eichholz JE, Walch H, Ilica AT, et al
    Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with SRS.
    Int J Radiat Oncol Biol Phys. 2025 Feb 8:S0360-3016(25)00093.
    PubMed     Abstract available
    
    
    
41. SHIN YS, Yun JK, Jung J, Park JH, et al
    Comparison of Metastasectomy and Stereotactic Body Radiation Therapy for Pulmonary Oligometastasis From Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Int J Radiat Oncol Biol Phys. 2025;121:432-441.
    PubMed     Abstract available
    
    
    
42. BRAGA-COHEN S, Lavigne J, Dos Santos M, Tarlet G, et al
    Evidence of Alveolar Macrophage Metabolic Shift Following Stereotactic Body Radiation Therapy -Induced Lung Fibrosis in Mice.
    Int J Radiat Oncol Biol Phys. 2025;121:506-519.
    PubMed     Abstract available
    
    
    
43. GLICKSMAN RM, Raman S, Ye XY, Bedard PL, et al
    The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2025;121:292-306.
    PubMed     Abstract available
    
    
    
44. MOUSTAKIS C, Blanck O, Grohmann M, Albers D, et al
    Planning Benchmark Study for Stereotactic Body Radiation Therapy of Pancreas Carcinomas With Simultaneously Integrated Boost and Protection: Results of the DEGRO/DGMP Working Group on Stereotactic Radiation Therapy and Radiosurgery.
    Int J Radiat Oncol Biol Phys. 2025;121:547-557.
    PubMed     Abstract available
    
    
    
45. SHARMA M, Naqa IE, Sneed PK
    Does time to retreatment matter? An NTCP model to predict radionecrosis after repeat SRS for recurrent brain metastases incorporating time-dependent discounted dose.
    Int J Radiat Oncol Biol Phys. 2025 Feb 1:S0360-3016(25)00080.
    PubMed     Abstract available
    
    
    January 2025
46. LATIFI A, Roumeliotis M, Quirk S, Gardner UG, et al
    Brachytherapy Seed Placement by Robotic Bronchoscopy with Cone-Beam CT Guidance for Peripheral Lung Cancer: A Human Cadaveric Feasibility Pilot.
    Int J Radiat Oncol Biol Phys. 2025 Jan 25:S0360-3016(25)00078.
    PubMed     Abstract available
    
    
    
47. NAGLER F, Vorbach S, Mohamed AA, Thaqi S, et al
    Pulmonary Stereotactic Body Radiotherapy of Oligometastatic Head-and-Neck Squamous Cell Carcinoma - A multicenter retrospective study.
    Int J Radiat Oncol Biol Phys. 2025 Jan 4:S0360-3016(24)03771.
    PubMed     Abstract available
    
    
    
48. MURTHY V, Mallick I, Maitre P, Mulye G, et al
    Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium.
    Int J Radiat Oncol Biol Phys. 2025 Jan 2:S0360-3016(24)03773.
    PubMed     Abstract available
    
    
    
49. SANGUINETI G, D'Urso P, Bottero M, Farneti A, et al
    Stereotactic Radiation Therapy in 3 Fractions for T1 Glottic Cancer.
    Int J Radiat Oncol Biol Phys. 2025;121:145-152.
    PubMed     Abstract available
    
    
    
50. BALAJI P, Liulu X, Sivakumar S, Chong JJH, et al
    Mechanistic Insights and Knowledge Gaps in the Effects of Radiation Therapy on Cardiac Arrhythmias.
    Int J Radiat Oncol Biol Phys. 2025;121:75-89.
    PubMed     Abstract available
    
    
    
51. SCHELLENBERG D, Gabos Z, Duimering A, Debenham B, et al
    Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.
    Int J Radiat Oncol Biol Phys. 2025;121:28-38.
    PubMed     Abstract available
    
    
    
52. WANG E, Abdallah H, Snir J, Chong J, et al
    Predicting the 3-Dimensional Dose Distribution of Multilesion Lung Stereotactic Ablative Radiation Therapy With Generative Adversarial Networks.
    Int J Radiat Oncol Biol Phys. 2025;121:250-260.
    PubMed     Abstract available
    
    
    
53. ZHANG P, Happersett L, Burleson S, Oh JH, et al
    Reduction of Postradiation Therapy Urinary Toxicity Via Intrafractional Megavoltage-Kilovoltage Prostate Location Monitoring.
    Int J Radiat Oncol Biol Phys. 2025;121:261-268.
    PubMed     Abstract available
    
    
    
54. TROJANI V, Grehn M, Botti A, Balgobind B, et al
    Refining Treatment Planning in STereotactic Arrhythmia Radioablation: Benchmark Results and Consensus Statement From the STOPSTORM.eu Consortium.
    Int J Radiat Oncol Biol Phys. 2025;121:218-229.
    PubMed     Abstract available
    
    
    
55. WANG Y, Dong X, Yan S, Liu B, et al
    Comparison of the Long-term Survival Outcome of Surgery versus Stereotactic Body Radiation Therapy as Initial Local Treatment for Pulmonary Oligometastases from Colorectal Cancer: A Propensity Score Analysis.
    Int J Radiat Oncol Biol Phys. 2025;121:45-55.
    PubMed     Abstract available
    
    
    December 2024
56. MAVRIKIOS A, Baldini C, Loriot Y, Henon C, et al
    Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?
    Int J Radiat Oncol Biol Phys. 2024;120:1245-1256.
    PubMed     Abstract available
    
    
    
57. NGUYEN TK, Ramadan S, Palma DA, Corkum MT, et al
    Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease.
    Int J Radiat Oncol Biol Phys. 2024;120:1231-1238.
    PubMed     Abstract available
    
    
    
58. WANG Q, Ji X, Sun J, Zhang A, et al
    Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.
    Int J Radiat Oncol Biol Phys. 2024;120:1363-1376.
    PubMed     Abstract available
    
    
    November 2024
59. THARIAT J, Bosset M, Falcoz A, Vernerey D, et al
    Survival without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomised Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using Stereotactic Ablative Radiotherapy (SABR)-alone or chemotherapy SABR.
    Int J Radiat Oncol Biol Phys. 2024 Nov 27:S0360-3016(24)03651.
    PubMed     Abstract available
    
    
    
60. KEANE FK, Yeap BY, Khandekar MJ, Lin JJ, et al
    Phase II trial of consolidative stereotactic body radiation therapy in patients with metastatic oncogene-driven non-small cell lung carcinoma treated with tyrosine kinase inhibitors.
    Int J Radiat Oncol Biol Phys. 2024 Nov 20:S0360-3016(24)03515.
    PubMed     Abstract available
    
    
    
61. DOHOPOLSKI M, Schmitt LG, Anand S, Zhang H, et al
    Exploratory Evaluation of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR) with CNS-Active Drugs in Brain Metastases Treatment.
    Int J Radiat Oncol Biol Phys. 2024 Nov 16:S0360-3016(24)03641.
    PubMed     Abstract available
    
    
    
62. SINGH M, Maitre P, Krishnan A, Adsul K, et al
    Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate.
    Int J Radiat Oncol Biol Phys. 2024;120:1011-1020.
    PubMed     Abstract available
    
    
    
63. EHRET F, Furweger C, Liegl R, Schmelter V, et al
    Tumor Control Probability and Time-Dose-Response Modeling for Stereotactic Radiosurgery of Uveal Melanoma.
    Int J Radiat Oncol Biol Phys. 2024;120:1052-1057.
    PubMed     Abstract available
    
    
    
64. SIMONE CB 2ND
    Enhancing Outcomes in Locally Advanced Non-Small Cell Lung Cancer Through Stereotactic Dose Escalation.
    Int J Radiat Oncol Biol Phys. 2024;120:695-697.
    PubMed    
    
    
    
65. GLICKSMAN RM, Berlin A, Helou J, Loblaw A, et al
    FASTRACKing Our Understanding of Renal Function After Kidney Stereotactic Ablative Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;120:655-657.
    PubMed    
    
    
    
66. ZHANG S, Simard M, Lapointe A, Filion E, et al
    Evaluation of Radiation Dose Effect on Lung Function Using Iodine Maps Derived From Dual-Energy Computed Tomography.
    Int J Radiat Oncol Biol Phys. 2024;120:894-903.
    PubMed     Abstract available
    
    
    
67. GAUDREAULT M, Hardcastle N, Jackson P, McIntosh L, et al
    Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma: TROG 15.03 FASTRACK II.
    Int J Radiat Oncol Biol Phys. 2024;120:648-654.
    PubMed     Abstract available
    
    
    October 2024
68. EHRET F, Baya LE, Erridge SC, Bussiere M, et al
    Radiotherapy for Meningiomas - Where Do We Stand and What's on the Horizon?
    Int J Radiat Oncol Biol Phys. 2024 Oct 28:S0360-3016(24)03525.
    PubMed     Abstract available
    
    
    
69. ZHANG X, Yan J, Lei Q, Neo J, et al
    A Randomised, Multicentre, Phase II Trial of Camrelizumab with or without Metastasis-directed Stereotactic Body Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma.
    Int J Radiat Oncol Biol Phys. 2024 Oct 23:S0360-3016(24)03512.
    PubMed     Abstract available
    
    
    
70. SADDOUGHI SA, Kern R
    Stereotactic Irradiation to Achieve Lung Volume Reduction (SILVR) Lining: We Can All Have a Piece of the Pie.
    Int J Radiat Oncol Biol Phys. 2024;120:357-358.
    PubMed    
    
    
    
71. LI GJ, Tan H, Nusrat H, Chang J, et al
    Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review.
    Int J Radiat Oncol Biol Phys. 2024;120:359-369.
    PubMed     Abstract available
    
    
    
72. KAMTAM DN, Binkley MS, Kapula N, Sadeghi C, et al
    First in Human Phase 1 Clinical Trial of Stereotactic Irradiation to Achieve Lung Volume Reduction (SILVR) in Severe Emphysema.
    Int J Radiat Oncol Biol Phys. 2024;120:345-356.
    PubMed     Abstract available
    
    
    September 2024
73. IGARASHI A, Onishi H, Shioyama Y, Matsumoto Y, et al
    Cost-Utility Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients With Stage I Non-small Cell Lung Cancer in Japan.
    Int J Radiat Oncol Biol Phys. 2024 Sep 28:S0360-3016(24)03174.
    PubMed     Abstract available
    
    
    
74. MACCHIA G, Campitelli M, Pezzulla D, Lucci S, et al
    STEREOTACTIC ABLATIVE RADIOTHERAPY FOR OLIGOMETASTATIC OVARIAN CANCER LYMPH NODE DISEASE: THE MITO-RT3/RAD PHASE II TRIAL: stereotactic radiotherapy for ovarian cancer nodal metastases.
    Int J Radiat Oncol Biol Phys. 2024 Sep 24:S0360-3016(24)03402.
    PubMed     Abstract available
    
    
    
75. KENNEDY TAC, Ong WL, Quon H, Cheung P, et al
    Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials.
    Int J Radiat Oncol Biol Phys. 2024 Sep 16:S0360-3016(24)03368.
    PubMed     Abstract available
    
    
    
76. GABRIELLA M, Donato P, Maura C, Donatella R, et al
    STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOPROGRESSIVE OVARIAN CANCER PATIENTS TREATED DURING PARP INHIBITOR MAINTENANCE: EFFICACY AND ADVERSE EVENTS FROM THE EPIMETHEO RETROSPECTIVE STUDY.
    Int J Radiat Oncol Biol Phys. 2024 Sep 8:S0360-3016(24)03369.
    PubMed     Abstract available
    
    
    
77. WOODY NM
    Spare the Knife When Retropharyngeal Lymph Nodes Are Present in Human Papillomavirus-Positive Oropharyngeal Cancer.
    Int J Radiat Oncol Biol Phys. 2024;120:13.
    PubMed    
    
    
    
78. KOLODZIEJ J, Pintea B, Bostrom JP, Pleger B, et al
    Pain Relief-Related Structural Brain Alterations in Trigeminal Neuralgia Induced by Noninvasive Stereotactic Radiosurgery: A Pilot Study.
    Int J Radiat Oncol Biol Phys. 2024;120:130-136.
    PubMed     Abstract available
    
    
    
79. TCHELEBI LT, Segovia D, Smith K, Shi Q, et al
    Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas.
    Int J Radiat Oncol Biol Phys. 2024;120:111-119.
    PubMed     Abstract available
    
    
    August 2024
80. TAN VS, Correa RJM, Nguyen TK, Louie AV, et al
    Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer (MISSILE): Long-Term Clinical Outcomes.
    Int J Radiat Oncol Biol Phys. 2024 Aug 8:S0360-3016(24)03173.
    PubMed     Abstract available
    
    
    
81. CHEN H, Atenafu EG, Zeng KL, Chan A, et al
    Magnetic Resonance Imaging Frequency After Stereotactic Body Radiation Therapy for Spine Metastases.
    Int J Radiat Oncol Biol Phys. 2024;119:1413-1421.
    PubMed     Abstract available
    
    
    
82. MORAES FY, Gouveia AG, Marta GN, da Silva MF, et al
    Meta-Analysis of Stereotactic Body Radiation ThERapy in Nonspine BONE Metastases (MASTER-BONES).
    Int J Radiat Oncol Biol Phys. 2024;119:1403-1412.
    PubMed     Abstract available
    
    
    July 2024
83. YOO Y, Gibson E, Zhao G, Re TJ, et al
    Extended nnU-Net for brain metastasis detection and segmentation in contrast-enhanced MRI with a large multi-institutional dataset.
    Int J Radiat Oncol Biol Phys. 2024 Jul 24:S0360-3016(24)03138.
    PubMed     Abstract available
    
    
    
84. SHER DJ, Avkshtol V, Moon D, Vo D, et al
    Stereotactic ablative radiotherapy for T1-2 glottic larynx cancer: mature results from the phase II LT-SABR trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 20:S0360-3016(24)02972.
    PubMed     Abstract available
    
    
    
85. LIU W, Feng H, Taylor PA, Kang M, et al
    NRG Oncology and Particle Therapy Co-Operative Group Patterns of Practice Survey and Consensus Recommendations on Pencil-Beam Scanning Proton Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies.
    Int J Radiat Oncol Biol Phys. 2024;119:1208-1221.
    PubMed     Abstract available
    
    
    
86. MOORE-PALHARES D, Zeng KL, Tseng CL, Chen H, et al
    Stereotactic Body Radiation Therapy for Sacral Metastases: Deviation From Recommended Target Volume Delineation Increases the Risk of Local Failure.
    Int J Radiat Oncol Biol Phys. 2024;119:1110-1121.
    PubMed     Abstract available
    
    
    
87. SINGH R, Valluri A, Lehrer EJ, Cao Y, et al
    Clinical Outcomes After Stereotactic Body Radiation Therapy for Nonspinal Bone Metastases: A Systematic Review and Meta-analysis.
    Int J Radiat Oncol Biol Phys. 2024;119:1099-1109.
    PubMed     Abstract available
    
    
    
88. KERBA M, Lourenco RA, Sahgal A, Cardet RF, et al
    An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases.
    Int J Radiat Oncol Biol Phys. 2024;119:1061-1068.
    PubMed     Abstract available
    
    
    
89. FREDMAN E, Moore A, Icht O, Tschernichovsky R, et al
    Acute toxicity and early PSA response after two-fraction stereotactic radiotherapy for localized prostate cancer using peri-rectal spacing - Initial report of the SABR-Dual trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 11:S0360-3016(24)02947.
    PubMed     Abstract available
    
    
    
90. TOESCA DAS, Hartsell WF, DeWees TA, Chang JH, et al
    Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial.
    Int J Radiat Oncol Biol Phys. 2024 Jul 5:S0360-3016(24)00669.
    PubMed     Abstract available
    
    
    
91. SCHEP DG, Vansantvoort J, Dayes I, Lukka H, et al
    Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma.
    Int J Radiat Oncol Biol Phys. 2024;119:832-837.
    PubMed     Abstract available
    
    
    June 2024
92. NI J, Chen H, Yu L, Guo T, et al
    Predicting regional recurrence and prognosis in stereotactic body radiotherapy-treated clinical stage I non-small cell lung cancer using a radiomics model constructed with surgical data.
    Int J Radiat Oncol Biol Phys. 2024 Jun 25:S0360-3016(24)00743.
    PubMed     Abstract available
    
    
    April 2024
93. GALLITTO M, Sedor G, Lee A, Pasetsky J, et al
    Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas: A Multicenter Study (STORM).
    Int J Radiat Oncol Biol Phys. 2024 Apr 17:S0360-3016(24)00515.
    PubMed     Abstract available
    
    
    
94. ZHAO J, Vaios E, Wang Y, Yang Z, et al
    Dose-Incorporated Deep Ensemble Learning for Improving Brain Metastasis SRS Outcome Prediction.
    Int J Radiat Oncol Biol Phys. 2024 Apr 12:S0360-3016(24)00505.
    PubMed     Abstract available
    
    
    
95. MEREDITH EG, Filion E, Faria S, Kundapur V, et al
    Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET).
    Int J Radiat Oncol Biol Phys. 2024 Apr 11:S0360-3016(24)00480.
    PubMed     Abstract available
    
    
    
96. BIN-ALAMER O, Abou-Al-Shaar H, Peker S, Samanci Y, et al
    Vestibular Schwannoma International Study of Active Surveillance Versus Stereotactic Radiosurgery: the VISAS Study.
    Int J Radiat Oncol Biol Phys. 2024 Apr 6:S0360-3016(24)00482.
    PubMed     Abstract available
    
    
    
97. BAKER S, Lechner L, Liu M, Chang JS, et al
    Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
    Int J Radiat Oncol Biol Phys. 2024;118:1497-1506.
    PubMed     Abstract available
    
    
    
98. LYNCH C, Korpics MC, Katipally RR, Wu T, et al
    Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
    Int J Radiat Oncol Biol Phys. 2024;118:1519-1530.
    PubMed     Abstract available
    
    
    
99. MERCIER C, Billiet C, Ost P, Joye I, et al
    Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;118:1490-1496.
    PubMed     Abstract available
    
    
    March 2024
100. YASAR B, Suh YE, Chapman E, Nicholls L, et al
     Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II trial.
     Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00425.
     PubMed     Abstract available
     
     
     
101. FAROOQI AS, Yoder AK, Lin HY, Pasalic D, et al
     SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.
     Int J Radiat Oncol Biol Phys. 2024;118:971-978.
     PubMed     Abstract available
     
     
     
102. NEILSEN BK, Ma TM, Akingbemi WO, Neylon J, et al
     Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Rad
     Int J Radiat Oncol Biol Phys. 2024;118:986-997.
     PubMed     Abstract available
     
     
     
103. MILANO MT, Doucette C, Mavroidis P, Yorke E, et al
     Hypofractionated Stereotactic Radiation Therapy Dosimetric Tolerances for the Inferior Aspect of the Brachial Plexus: A Systematic Review.
     Int J Radiat Oncol Biol Phys. 2024;118:931-943.
     PubMed     Abstract available
     
     
     
104. LIU YC, Schmidt RO, Kapadia NS, Phillips JD, et al
     Disparities in access to multidisciplinary cancer consultations and treatment for early-stage non-small cell lung cancer patients: A SEER-Medicare analysis.
     Int J Radiat Oncol Biol Phys. 2024 Mar 13:S0360-3016(24)00426.
     PubMed     Abstract available
     
     
     
105. YAN W, Ren Z, Chen X, Zhang R, et al
     Potential role of lymphocyte CD44 in determining treatment selection between stereotactic body radiotherapy and surgery for early-stage non-small-cell lung cancer.
     Int J Radiat Oncol Biol Phys. 2024 Mar 4:S0360-3016(24)00356.
     PubMed     Abstract available
     
     
     February 2024
106. PATEL KR, Rydzewski NR, Schott E, Cooley-Zgela T, et al
     A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy.
     Int J Radiat Oncol Biol Phys. 2024 Feb 28:S0360-3016(24)00323.
     PubMed     Abstract available
     
     
     
107. BASCHNAGEL AM, Flakus MJ, Wallat EM, Wuschner AE, et al
     A Phase 2 Randomized Clinical Trial Evaluating 4DCT Ventilation-based Functional Lung Avoidance Radiotherapy for Non-Small Cell Lung Cancer.
     Int J Radiat Oncol Biol Phys. 2024 Feb 20:S0360-3016(24)00327.
     PubMed     Abstract available
     
     
     
108. WILLIAMS TM, Miller E, Welliver M, Brownstein J, et al
     A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
     Int J Radiat Oncol Biol Phys. 2024 Feb 20:S0360-3016(24)00324.
     PubMed     Abstract available
     
     
     
109. REDMOND KJ, Hattangadi-Gluth J, Pollum EL, Trifiletti DM, et al
     Navigating the Spinal Frontier: Recent Data on Stereotactic Body Radiation Therapy for Spine Metastases.
     Int J Radiat Oncol Biol Phys. 2024;118:313-317.
     PubMed    
     
     
     
110. MITTAUER KE, Tolakanahalli R, Kotecha R, Chuong MD, et al
     Commissioning Intracranial Stereotactic Radiosurgery for a Magnetic Resonance-Guided Radiation Therapy (MRgRT) System: MR-RT Localization and Dosimetric End-to-End Validation.
     Int J Radiat Oncol Biol Phys. 2024;118:512-524.
     PubMed     Abstract available
     
     
     
111. REMMERTS DE VRIES IF, Verbakel WFAR, Adema M, Slotman BJ, et al
     Spine Stereotactic Body Radiation Therapy Without Immobilization: Detailed Analysis of Intrafraction Motion Using High-Frequency kV Imaging During Irradiation.
     Int J Radiat Oncol Biol Phys. 2024;118:525-532.
     PubMed     Abstract available
     
     
     
112. BAE SH, Chun SJ, Chung JH, Kim E, et al
     Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.
     Int J Radiat Oncol Biol Phys. 2024;118:337-351.
     PubMed     Abstract available
     
     
     January 2024
113. CHEN ATC, Serante AR, Ayres AS, Tonaki JO, et al
     Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiotherapy of 25 Gy in 5 fractions compared to 35 Gy in 5 fractions in the Reirradiation of Recurrent Glioblastoma.
     Int J Radiat Oncol Biol Phys. 2024 Jan 15:S0360-3016(24)00026.
     PubMed    
     
     
     
114. TRAN PT, Mouw KW
     SABR Today . . . and Tomorrow?
     Int J Radiat Oncol Biol Phys. 2024;118:11.
     PubMed    
     
     
     
115. VELLAYAPPAN B, Lim-Fat MJ, Kotecha R, De Salles A, et al
     A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations.
     Int J Radiat Oncol Biol Phys. 2024;118:14-28.
     PubMed     Abstract available
     
     
     December 2023
116. NEYLON J, Ma TM, Savjani R, Low DA, et al
     Quantifying Intrafraction Motion and the Impact of Gating for MRI-guided Stereotactic Radiotherapy for Prostate Cancer: Analysis of the MRI arm from the MIRAGE Phase III Randomized Trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 29:S0360-3016(23)08309.
     PubMed     Abstract available
     
     
     
117. ACHARD V, Zilli T, Lamanna G, Jorcano S, et al
     Urethra-sparing prostate cancer stereotactic body radiotherapy: sexual function and radiation dose to the penile bulb, the crura, and the internal pudendal arteries from a randomized phase 2 trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 29:S0360-3016(23)08307.
     PubMed     Abstract available
     
     
     
118. RIMNER A, Gelblum DY, Wu AJ, Shepherd AF, et al
     Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-small Cell Lung Cancer - A Phase I Dose Escalation Trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 26:S0360-3016(23)08252.
     PubMed     Abstract available
     
     
     
119. VAIOS EJ, Shenker RF, Hendrickson PG, Wan Z, et al
     Long-term Intracranial Outcomes with Combination Dual Immune-Checkpoint Blockade and SRS in Patients with Melanoma and NSCLC Brain Metastases.
     Int J Radiat Oncol Biol Phys. 2023 Dec 12:S0360-3016(23)08234.
     PubMed     Abstract available
     
     
     
120. BASSETTI MF, Morris BA, Sethakorn N, Lang JM, et al
     Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase Ib Trial.
     Int J Radiat Oncol Biol Phys. 2023 Dec 8:S0360-3016(23)08166.
     PubMed     Abstract available
     
     
     
121. DUDAS D, Saghad PG, Dilling TJ, Perez BA, et al
     Deep Learning-Guided Dosimetry for Mitigating Local Failure of Non-Small Cell Lung Cancer Patients Receiving SBRT.
     Int J Radiat Oncol Biol Phys. 2023 Dec 4:S0360-3016(23)08185.
     PubMed     Abstract available
     
     
     
122. SAFAVI AH, Palma DA, Giuliani ME
     Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?
     Int J Radiat Oncol Biol Phys. 2023;117:1232-1235.
     PubMed    
     
     
     
123. SIVA S, Staehler M
     The Right Tool for the Job: The Knife, the SABR, or Fire and Ice?
     Int J Radiat Oncol Biol Phys. 2023;117:1047.
     PubMed    
     
     
     
124. GHALIBAFIAN M, Mirzaei S, Girinsky T, Sadeghi Y, et al
     Challenges in Treating Childhood Infratentorial Ependymoma: A Low- and Middle-Income Country Experience.
     Int J Radiat Oncol Biol Phys. 2023;117:1181-1190.
     PubMed     Abstract available
     
     
     
125. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
     Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors.
     Int J Radiat Oncol Biol Phys. 2023;117:1222-1231.
     PubMed     Abstract available
     
     
     
126. LAWRENCE TS, Aryal MP, Evans JR, Cuneo KC, et al
     Does Vascular Collapse Occur After Treatment of Hepatocellular Cancer With Stereotactic Body Radiation Therapy?
     Int J Radiat Oncol Biol Phys. 2023;117:1236-1240.
     PubMed     Abstract available
     
     
     November 2023
127. RITTER AR, Miller ED
     No Regrets About SABR for NETs.
     Int J Radiat Oncol Biol Phys. 2023;117:786.
     PubMed    
     
     
     
128. PARIKH PJ, Lee P, Low DA, Kim J, et al
     A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
     Int J Radiat Oncol Biol Phys. 2023;117:799-808.
     PubMed     Abstract available
     
     
     September 2023
129. JEON SH, Jang BS, Kim DY, Kim JH, et al
     Dynamic responses of circulating T cells following stereotactic body radiotherapy for bone metastasis in patients with breast cancer.
     Int J Radiat Oncol Biol Phys. 2023 Sep 22:S0360-3016(23)07932.
     PubMed     Abstract available
     
     
     
130. LIU F, Ververs JD, Farris MK, William Blackstock A Jr, et al
     Optimal Radiotherapy Fractionation Regimens for Early-Stage Non-Small-Cell Lung Cancer.
     Int J Radiat Oncol Biol Phys. 2023 Sep 19:S0360-3016(23)07929.
     PubMed     Abstract available
     
     
     
131. PRABHU RS, Akinyelu T, Vaslow ZK, Matsui JK, et al
     Single Fraction vs. Fractionated Preoperative Radiosurgery for Resected Brain Metastases: a PROPS-BM International Multicenter Cohort Study.
     Int J Radiat Oncol Biol Phys. 2023 Sep 15:S0360-3016(23)07924.
     PubMed     Abstract available
     
     
     
132. ZABROCKA E, Polce S, Roberson JD, Wu J, et al
     Utility of Stereotactic Body Radiation Therapy (SBRT) in Establishing Local Control for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery.
     Int J Radiat Oncol Biol Phys. 2023 Sep 12:S0360-3016(23)07908.
     PubMed     Abstract available
     
     
     
133. OWEN D, Siva S, Salama JK, Daly M, et al
     Some Like It Hot: The Value of Dose and Hot Spots in Lung Stereotactic Body Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2023;117:1-5.
     PubMed    
     
     
     
134. MENDEZ ROMERO A, van der Holt B, Willemssen FEJA, de Man RA, et al
     Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial).
     Int J Radiat Oncol Biol Phys. 2023;117:45-52.
     PubMed     Abstract available
     
     
     
135. REYNGOLD M, Karam SD, Hajj C, Wu AJ, et al
     Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer.
     Int J Radiat Oncol Biol Phys. 2023;117:53-63.
     PubMed     Abstract available
     
     
     August 2023
136. GUAN J, Sun K, Guerrero CA, Zheng J, et al
     A Phase 2 study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.
     Int J Radiat Oncol Biol Phys. 2023 Aug 23:S0360-3016(23)07836.
     PubMed     Abstract available
     
     
     
137. UPADHYAY R, Ayan AS, Jain S, Klamer BG, et al
     Dose/volume tolerance of the brain and predictors of radiation necrosis after three-fraction radiosurgery for brain metastases: A large single-institutional analysis.
     Int J Radiat Oncol Biol Phys. 2023 Aug 11:S0360-3016(23)07730.
     PubMed     Abstract available
     
     
     
138. SHINYA Y, Hasegawa H, Shin M, Kashiwabara K, et al
     Age-Dependent Hemorrhage Risk and Obliteration Benefit After Radiosurgery for Brain Arteriovenous Malformation.
     Int J Radiat Oncol Biol Phys. 2023;116:1126-1134.
     PubMed     Abstract available
     
     
     July 2023
139. KIM IA, Winter KA, Sperduto PW, Santos JFL, et al
     Concurrent lapatinib with brain radiotherapy in HER2+ breast cancer patients with brain metastases - NRG ONCOLOGY-KROG/ RTOG 1119 phase II randomized trial.
     Int J Radiat Oncol Biol Phys. 2023 Jul 26:S0360-3016(23)07681.
     PubMed     Abstract available
     
     
     
140. OLIVER DE, Laborde JM, Singh DP, Milano MT, et al
     Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience.
     Int J Radiat Oncol Biol Phys. 2023;116:849-857.
     PubMed     Abstract available
     
     
     
141. AMINI A, Rusthoven CG
     Ablative Radiation Therapy for Oligometastatic EGFR-Mutated Non-small Cell Lung Cancer: Who, Why, When, and How?
     Int J Radiat Oncol Biol Phys. 2023;116:481.
     PubMed    
     
     
     June 2023
142. CRUZ-LIM EM, Cereno RE, Canal JP, Vega G Jr, et al
     Challenges to Improving Access to Stereotactic Body Radiation Therapy and Radiosurgery in the Philippines: A Case Study for Lower-Middle Income Countries.
     Int J Radiat Oncol Biol Phys. 2023;116:430-438.
     PubMed    
     
     
     May 2023
143. MORRIS BA, Holmes EE, Anger NJ, Cooley G, et al
     Toxicity and Patient Reported QoL Outcomes Following Prostate SBRT with Focal Boost to MRI Identified Prostate Cancer Lesions: Results of a Phase II Trial.
     Int J Radiat Oncol Biol Phys. 2023 May 11:S0360-3016(23)00446.
     PubMed     Abstract available
     
     
     April 2023
144. ECHEVARRIA MI, Yang GQ, Chen DT, Kirtane K, et al
     Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent squamous cell carcinoma of the head and neck.
     Int J Radiat Oncol Biol Phys. 2023 Apr 25:S0360-3016(23)00366.
     PubMed     Abstract available
     
     
     
145. BUCKNELL NW, Kron T, Herschtal A, Hardcastle N, et al
     Comparison of changes in pulmonary function following stereotactic body radiotherapy versus conventional 3D conformal radiotherapy for stage I and IIa non-small cell lung cancer: an analysis of the TROG 09.02 (CHISEL) phase III trial.
     Int J Radiat Oncol Biol Phys. 2023 Apr 20:S0360-3016(23)00369.
     PubMed     Abstract available
     
     
     
146. WU TC, Stube A, Felix C, Oseguera D, et al
     Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC).
     Int J Radiat Oncol Biol Phys. 2023 Apr 4:S0360-3016(23)00325.
     PubMed     Abstract available
     
     
     
147. GREER MD, Koger B, Glenn M, Kang J, et al
     Predicted Inferior Outcomes for Lung SBRT With Treatment Planning Systems That Fail Independent Phantom-Based Audits.
     Int J Radiat Oncol Biol Phys. 2023;115:1301-1308.
     PubMed     Abstract available
     
     
     March 2023
148. NGUYEN EK, Poon I, Ung YC, Tsao M, et al
     Toxicity and Efficacy of Multitarget Thoracic Stereotactic Body Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2023;115:897-905.
     PubMed     Abstract available
     
     
     
149. SONG X, Wei J, Sun R, Jiang W, et al
     Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Pain Relief for Bone Metastases: A Systematic Review and Meta-Analysis.
     Int J Radiat Oncol Biol Phys. 2023;115:909-921.
     PubMed     Abstract available
     
     
     February 2023
150. LIVERINGHOUSE CL, Mills MN, Ahmed KA, Washington IR, et al
     Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy.
     Int J Radiat Oncol Biol Phys. 2023 Feb 14:S0360-3016(22)03689.
     PubMed     Abstract available
     
     
     January 2023
151. LEHRER EJ, Kowalchuk RO, Gurewitz J, Bernstein K, et al
     Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiat
     Int J Radiat Oncol Biol Phys. 2023 Jan 20:S0360-3016(23)00057.
     PubMed     Abstract available
     
     
     October 2022
152. ARCIDIACONO F, Anselmo P, Casale M, Zannori C, et al
     STereotactic Ablative RadioTherapy in NEWly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrEnt RAdio-chemotherapy: early analysis of the START-NEW-ERA non-randomised phase II trial.
     Int J Radiat Oncol Biol Phys. 2022 Oct 23. pii: S0360-3016(22)03459.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neurosurgery is free of charge.